Evorin pharma

Evorin pharma http://evorin.com/ Professional treatment with the most scientifically advanced solutions

Evorin pharma is a leading health services and innovation company on a mission to continuously generate groundbreaking ideas in the name of Health and beauty. We have years of experience in developing innovative products and unique treatment methods and we promise to continue this tradition of excellence. Building a unique portfolio of Health and beauty and related brands, striving to surpass competitors in quality, innovation, and value, and elevating Evorin's image to become the world's most trusted Pharmaceutical and Cosme-ceutical company.

Medical innovation takes center stage in state legislaturesRecently, PhRMA had the opportunity to partner with the Natio...
28/08/2025

Medical innovation takes center stage in state legislatures

Recently, PhRMA had the opportunity to partner with the National Conference of State Legislatures (NCSL) for a panel discussion at their 2025 Legislative Summit in Boston, Massachusetts. The panel discussion centered around groundbreaking U.S. biopharmaceutical innovations, the positive impact for patients globally, and the policies that can nurture and protect them for generations to come.

Nearly all innovative, impactful medicines have one thing in common: They start and end in the states.

States play a critical role in providing an environment where academic institutions, research centers and private companies collaborate. Clinical trials also take place in communities across the country, giving patients access to promising treatments. And, once approved, medicines are delivered back through local doctors, hospitals and pharmacists.

Innovation is deeply human. During the panel, we heard stories about:

HIV/AIDS: How grassroots care and community models can help bridge trust and connect patients in marginalized communities with innovative treatments.
Rare disease & NICU care: One panelist shared how access to cutting-edge clinical trials in his home state of Massachusetts saved his premature twins, showing how location and access can mean the difference between life and loss.
Cancer & beyond: New medicines contributed to 1.3 million fewer cancer deaths (2000–2016). Cardiovascular and mental health therapies are reshaping outcomes for patients nationwide.
Even when a drug doesn’t make it to approval, the search itself strengthens local and state economies:

The biopharmaceutical sector supports more than 90,000 jobs in Massachusetts.
North Carolina hosts nearly 800 life sciences companies employing 70,000 people.
Across the U.S., the biopharmaceutical sector drives $1.6 trillion in economic output with facilities in 48 states.
Bottom line: With the right political environment, states are the perfect place to host collaboration, bring promising treatments to patients through clinical trials, and act as the hub for significant economic and workforce benefits in the process.

AI-enhanced echocardiography improves early detection of amyloid buildup in the heartAn artificial intelligence (AI) mod...
21/08/2025

AI-enhanced echocardiography improves early
detection of amyloid buildup in the heart

An artificial intelligence (AI) model
developed by Mayo Clinic and Ultromics, Ltd.,
an AI echocardiography company based in
Oxford, England, is highly accurate in
screening for cardiac amyloidosis, a rare and
progressive type of heart failure, according
to a new study. The model is the first and
only AI tool of its kind.

Researchers from Mayo Clinic and Ultromics,
with investigators at the University of
Chicago Medicine and collaborators around the
world, validated and tested the model on a
large and multiethnic patient population and
compared its abilities to other diagnostic
methods for cardiac amyloidosis.

Their findings, published in the European
Heart Journal, show that the AI model was
highly accurate, with 85% sensitivity
(correctly identifying those with the disease)
and 93% specificity (correctly identifying
those without the disease). Using a single
echocardiography videoclip, the model was
effective across all major types of cardiac
amyloidosis and distinguished it from other
conditions with similar characteristics.

Cardiac amyloidosis is a life-threatening
condition where an abnormal protein, called
amyloid, builds up in the heart, causing it to
stiffen and not work properly. It is often
missed because the symptoms and imaging
features can be similar to other heart
conditions. However, early diagnosis is
crucial because new drug therapies are now
available that can slow or stop the disease's
progression.

This work builds on the previous experience of
Mayo Clinic and Ultromics in developing an AI
echocardiography model to detect heart failure
with preserved ejection fraction (HFpEF),
which received Food and Drug Administration
(FDA) clearance in 2022. HFpEF is a common
type of heart failure, associated with high
morbidity and mortality, but can be
challenging to diagnose. An estimated 15% of
patients with HFpEF have cardiac amyloidosis.

"This AI model is a breakthrough tool that can
help us identify patients earlier so they can
receive the treatment they need," says
Patricia Pellikka, M.D., a cardiologist at
Mayo Clinic and past director of the Mayo
Clinic Echocardiography Lab in Rochester. "We
found that AI performed better than
traditional clinical and transthoracic echo-
based screening methods, providing clinicians
with stronger insights on which to base
decisions for further confirmation tests. New
treatments are available for cardiac
amyloidosis but are most effective if
administered early in the course of the
disease." Dr. Pellikka is senior author of the
study.

The amyloid AI model is FDA-cleared and is
currently being used at multiple centers in
the U.S. Dr. Pellikka says she looks forward
to applying this technology in the clinical
practice at Mayo Clinic.

This study was partially supported by a grant
from Ultromics and Dr. Pellikka is supported
as the Betty Knight Scripps-George M. Gura,
Jr., M.D. Professor of Cardiovascular Diseases
Clinical Research at Mayo Clinic. Mayo Clinic
has a financial interest in this technology
and will use any revenue it receives to
support its not-for-profit mission in patient
care, education and research.

BP Meds Should Begin Promptly, New ACC/AHA Guidelines SayThe target blood pressure level for adults remains below 130/80...
15/08/2025

BP Meds Should Begin Promptly, New ACC/AHA
Guidelines Say

The target blood pressure level for adults
remains below 130/80 mm Hg, but drug therapy
should be initiated sooner, according to new
guidelines published Thursday by the American
Heart Association (AHA) and American College
of Cardiology (ACC). Eleven other medical
organizations endorsed the new guidelines,
which replace those issued in 2017.

“We’re trying to get started earlier in the
process of preventing cardiovascular disease,”
said Daniel W. Jones, MD, dean and professor
emeritus of the University of Mississippi
School of Medicine in Jackson, who chaired the
guidelines committee.

Almost half of American adults have
hypertension, according to the AHA.

In the previous guidelines, a systolic blood
pressure of 140 mm Hg or higher or a diastolic
blood pressure of 90 mm Hg and above were the
thresholds to initiate medications for primary
prevention. The new guidelines recommend drug
therapy if blood pressure remains at or above
130/80 mm Hg after 3-6 months of lifestyle
changes such as eating a healthier diet.

Antihypertensive medications should begin
right away in adults with hypertension with
diabetes or chronic kidney disease or an
elevated 10-year risk of cardiovascular
disease, per the guidelines. The
cardiovascular disease risk calculation should
be based on the PREVENT risk calculator
published by the AHA in 2023.

While the target blood pressure goal is below
130/80 mm Hg, Jones said clinicians should
encourage patients to achieve readings lower
than 120/80 mm Hg when possible. The AHA and
ACC continue to recommend the heart-friendly
DASH diet that emphasizes fruits, vegetables,
fat free or low fat dairy products, fish,
poultry, beans, and nuts.

Recent Research Spurred Review
The new guidelines incorporate research about
controlling high blood pressure from 2015 to
2024. One new focus this time is the link
between high blood pressure and dementia.

“Lowering blood pressure in an intensive way
reduces the risk of dementia,” Jones said.

In addition to medication as appropriate,
reducing salt intake, staying physically
active, lowering weight, and managing stress
can all blunt the risk for dementia, the
authors of the guidelines found. Doing so
would also reduce risks for heart attack,
stroke, heart failure, and kidney disease,
they noted.

The guidelines also call for screening for
primary aldosteronism in patients with
resistant hypertension, regardless of whether
they have hypokalemia.

The document also makes two “important”
changes to laboratory testing: testing the
ratio of urine albumin and creatinine for all
patients with high blood pressure — which
formerly was considered an optional test — and
developing tailored approaches to medication
for high blood pressure.

The new guidelines suggest patients discuss
renal denervation with their clinicians as a
way to reduce the need for medication, but the
document falls short of recommending the
procedure.

The 2017 guidelines advised no more than 2300
mg of sodium intake per day; now the
recommendation is to cap sodium at 1500 mg per
day. And people who want to prevent or manage
hypertension should not drink alcohol at all,
according to the new guidelines.

Men who drink should limit their intake to two
alcoholic beverages per day; women to one.
That’s a daily limit, not a rolling average,
Jones stressed. Saving drinks for the weekend
is not a thing when blood pressure management
is concerned.

“Losing weight lowers blood pressure,” added
Jones, who encouraged patients to consider
using a GLP-1 inhibitor when clinically
appropriate. Women who are pregnant or
expecting to become pregnant should consider
using low-dose aspirin to prevent risk of
preeclampsia, the guidelines state.

“High blood pressure during pregnancy predicts
high blood pressure for the rest of your
life,” Jones said. Given this reality the new
guidelines spend more time on pregnancy than
the previous version.

Scientists Discover the Brain’s “Reset Button” That Separates Your MemoriesA brainstem region helps punctuate memories. ...
09/08/2025

Scientists Discover the Brain’s “Reset Button”
That Separates Your Memories

A brainstem region helps punctuate memories.
Stress may block its ability to mark new
experiences.

Although life unfolds in a continuous flow,
our memories don’t capture it that way. We
don’t recall the past as one seamless timeline
but rather as a sequence of distinct,
meaningful moments—much like how sentences are
broken up with grammar and punctuation. This
mental structure gives our experiences clarity
and helps us understand both what happened and
when it occurred.

The brain must devote a lot of space to this
herculean task, right?

Wrong! It turns out that a tiny but mighty
region pulls far more than its weight.

In a study published in Neuron, psychologists
from UCLA and Columbia University used brain
imaging and pupil measurements to reveal that
a tiny group of neurons in the brainstem,
called the locus coeruleus, functions like a
“memory reset button” when meaningful changes
occur.

“Our key question was: as an experience
unfolds, how does the brain ‘know’ when one
meaningful memory has ended and the next
should begin?” said UCLA psychology professor
and first author David Clewett. “Research has
shown that remaining in a stable context, such
as the same room, binds sequential experiences
together in memory. By contrast, experiencing
a shift in context, or event boundary, drives
memories apart to represent distinct events.
In this way, context acts as the grammar of
human memory. What we found is that the locus
coeruleus is most active at event boundaries
when memories become separated. Thus, this
small region at the core of the brain’s
arousal system may serve to punctuate our
thoughts and memories.”

Auditory cues shape context and memory
Clewett, along with co-authors Ringo Huang
from UCLA and Lila Davachi from Columbia,
conducted an experiment with 32 participants
who viewed images of neutral objects while
undergoing MRI scanning. To simulate changes
in context, the researchers played simple
tones in either the left or right ear. When
eight identical tones were played repeatedly
in the same ear, it created the feeling of a
continuous event. A shift in tone pitch, and
ear location signaled a change, creating the
perception of an event boundary. This
alternating pattern continued, generating the
impression of four distinct auditory events.

Next, the team evaluated how these context
shifts affected memory. They hypothesized that
the ability to recall the correct order of
events would reflect whether the experiences
had been stored as a single episode or
separated into distinct memories. When events
are encoded together, sequence recall should
be easier; when they are stored apart, it
becomes more difficult.

As expected, increased activity in the locus
coeruleus during event boundaries was linked
to poorer recall of the order of item pairs
that crossed those boundaries, suggesting the
memories had been stored separately. To
validate this, the researchers compared their
fMRI readings of locus coeruleus activity with
measurements of pupil dilation taken at the
same time, since pupil size tends to increase
during new events and locus coeruleus
activation. The consistency between these data
confirmed that the fMRI signals were
accurately capturing activity in this small
brain region. Functional magnetic resonance
imaging, or fMRI, monitors brain activity by
measuring changes in blood flow while
participants are inside the scanner.

How hippocampus responds to boundary signals
The impact of this neural “reset” signal
extended well beyond initial memory
segmentation. Higher levels of locus coeruleus
activity at event boundaries were linked to
more pronounced shifts in activation within
the hippocampus—a brain region crucial for
encoding new memories and tracking contextual
information such as location and timing.

“Part of the job of the hippocampus is to map
the structure of our experiences, so it has an
index of the beginning, middle, and ends of
events. We found that the locus coeruleus may
provide the critical ‘start’ signal to the
hippocampus, as if saying, ‘Hey, we’re in a
new event now,’” said Davachi. “Prior work had
shown that bursts of locus coeruleus activity
help reconfigure brain networks to direct
attention to new and important experiences.
Our findings suggest that this updating signal
is even more widespread, also reaching
memory-related regions that carry
representations of ongoing events.”

The researchers also examined how brief bursts
of locus coeruleus activation are influenced
by background levels of locus coeruleus
activity. This matters because locus coeruleus
neurons operate in two distinct modes: a
burst-like mode that flags significant events
and forms new memories, and a background mode
that regulates general alertness and stress.

“The locus coeruleus is like the brain’s
internal alarm system,” Clewett said. “But
under chronic stress, this system becomes
overactive. The result is like living with a
fire alarm that never stops ringing, making it
difficult to notice when a real fire breaks
out.”

Although the dynamic interplay between these
firing patterns has been studied in the
context of decision-making, perception, and
learning, its relevance for how we perceive
and remember events has, thus far, been
unclear. So, the authors set out to test
whether bursts of locus coeruleus activation
at event boundaries, the neural signals that
segment memories, might be weakened or lost
under conditions of chronic stress. This
question posed a challenge, as fMRI alone
cannot measure absolute levels of stress or
locus coeruleus activation. To address this,
they used an imaging method that indirectly
measures neuromelanin, a pigmented
neurochemical that accumulates in the locus
coeruleus with repeated activation over time.

Stress weakens the brain’s event detection
signals
As predicted, participants with a higher
neuromelanin-related signal, thought to
indicate chronic stress, showed weaker pupil
dilation responses to event boundaries.
Stronger low-frequency fluctuations in locus
coeruleus activation, a proxy for background
levels of activity, also predicted weaker
spikes in locus coeruleus activation and pupil
responses to boundaries during the task.
Together, these findings suggest that chronic
hyperarousal may blunt one’s sensitivity to
change, disrupting the cues that anchor and
organize new episodes in memory.

Identification of the locus coeruleus as the
gateway or conductor for memory formation may
lead to better ways to treat PTSD and other
memory-related disorders, such as Alzheimer’s
disease, where the locus coeruleus is
unusually hyperactive. There are potential
ways to quiet an overactive locus coeruleus,
whether pharmacologically or through slow-
paced breathing or even hand-squeezed stress
balls. But good long-term solutions require
further research and will take time to
discover and bring to market. Perceiving
events in the “right” way is directly linked
to better memory, suggesting that improving
locus coeruleus function is an effective
target for either protecting or recovering
memory function.

Clewett said that the sophisticated tools
necessary to look into the brain require the
kind of funding that only the federal
government can provide. Clewett said that
several NIH grants that funded this research
paid for the scanning and facilities they used
to do the experiments, for example.

“Conducting basic science and clinical
research is critical for opening new doors for
treating debilitating disorders,” Clewett
said. “Recent legislative actions threaten
this future, not only for scientific research
but for breakthroughs that can improve the
lives of patients and their families. It is
perhaps ironic that at a time when legislation
promises ‘big and beautiful change,’ it turns
out one of the brain’s smallest players may
have the biggest impact on how we understand
and remember our lives.”

New technology successfully monitors cancer progression at the cellular levelCellular imaging and segmentation within th...
17/07/2025

New technology successfully monitors cancer
progression at the cellular level

Cellular imaging and segmentation within the
MEA platform. Credit: Science Advances (2025).
DOI: 10.1126/sciadv.adx4919
Sensome, the pioneer of microsensing
technology for real-time, in situ tissue
analysis, today announced the publication of a
study in Science Advances unveiling an
innovative methodology using its technology to
noninvasively monitor cell spatiotemporal
dynamics involved in cancer progression in a
real-time and label-free manner, which can
provide new insights for cancer diagnosis and
treatment.

The new methodology combines the use of
microelectrode arrays, electrical impedance
spectroscopy (EIS) that measures the
characteristics of tissue surrounding the
sensor, and predictive algorithms. The use of
predictive algorithms allows for faster
prediction, better resilience to noise, and
recognition of complex data patterns when
compared to traditional EIS analysis
approaches. This new methodology is believed
to be the first-ever use of EIS to enable
quantitative real-time monitoring of cell
spatiotemporal dynamics, or cell changes over
time.

The research was a multi-year endeavor led by
Sensome and École Polytechnique, in
collaboration with the Center for Nanoscience
and Nanotechnology (C2N). In the study, the
team at École Polytechnique's Hydrodynamics
Laboratory (LadHyX) leveraged Sensome's
technology and exposed it to normal and
cancerous breast epithelial cells, where it
was able to accurately predict the
spatiotemporal evolution of cell density, cell
substrate coverage, mean cell diameter, and
cell type in agreement with microscopy
findings.

It also enabled real-time tracking of spatial
heterogeneities in breast cancer cell growth
and the competition between normal and
cancerous cells based on the EIS measurements
alone.

This technology has the potential to obviate
the need for microscopy imaging in cancer cell
monitoring in various settings and
significantly advance our understanding of
cancer cell behavior and interactions," said
co-author Abdul Barakat, CNRS Director of
Research and Professor at École Polytechnique.
Assessing how cells organize in space and time
is essential to elucidating cancer
progression.

Live-cell fluorescence microscopy is the
predominant method for tracking these dynamics
today but is often limited by cytotoxicity
induced by the fluorescent dyes, by cellular
photo-damage during extended periods of
microscopic imaging, and by restrictions in
optical access in the case of opaque clinical
samples. This methodology using Sensome's
technology demonstrates a noninvasive, label-
free method enabling long-term monitoring of
cancer-related cellular spatiotemporal
dynamics with minimal disruption of natural
cellular processes."

This study shows that the proprietary signal
processing and machine learning algorithms
involved in our technology can empower a
method to successfully monitor cancer cell
differentiation and evolution over time," said
Franz Bozsak, CEO and co-founder of Sensome.

This breakthrough is the first step in
exploring the use of our tissue-sensing
technology in monitoring cancer-related
phenomena, such as tumor growth. It
complements the work we are currently doing in
lung cancer—where in-situ cancer detection is
crucial—which is one of several applications
where we are applying our mastery of
electrical impedance spectroscopy to novel
uses in medicine. We are actively seeking
industrial partners to realize innovative
medical devices centered on our technology.

MIT's smart implant dispenses life-saving drug when diabetics need it mostHypoglycemia – a condition in which low blood ...
10/07/2025

MIT's smart implant dispenses life-saving drug
when diabetics need it most

Hypoglycemia – a condition in which low blood
glucose levels can cause you to feel dizzy,
weak, and shaky – can catch you by surprise.
It often occurs due to excess insulin, whether
it's produced by your body or if you've
injected too much of it.

There are ways to treat it quickly, but if
hypoglycemia strikes when you're asleep, or
affects children who can't jab themselves with
a glucagon injection, it can lead to a range
of disorienting symptoms and more dangerous
complications.

To counteract this condition, a team of
engineers at the Massachusetts Institute of
Technology (MIT) has developed a coin-sized
device that can be safely implanted in the
body to automatically deliver a dose of
glucagon when a sensor notices blood glucose
levels dropping too low – and potentially save
the user's life.

The compact device that's designed to be
implanted under the skin only weighs 0.07 oz
(2 g), and features a tiny reservoir for
glucagon, a hormone that stimulates your liver
to release glucose into your bloodstream.
That's also what people with hypoglycemia,
including some folks with Type 1 diabetes,
carry along with them at all times in the form
of a preloaded syringe to inject whenever
they're feeling the symptoms of the condition
coming on.

What's different here is the glucagon in the
reservoir is a specially developed powdered
version, which remains stable for longer. The
reservoir itself is made from a 3D-printed
polymer, sealed with a nickel-titanium shape-
memory alloy that curls from a flat slab into
a U-shape when it's heated up to 104 °F (40
°C).

The tiny implant also includes an antenna that
receives a signal from a remote trigger or a
system that works with a glucose monitor. This
will power on a small electrical current and
heat the reservoir seal up to its temperature
threshold. At that point, the glucagon is
released into the body.

The researchers tested the device by
implanting it in diabetic mice, and found that
it helped bring their blood sugar levels back
to normal within 10 minutes of being triggered
when their glucose readings were dropping. The
device also proved to be similarly effective
in dispensing powdered epinephrine, which can
help to quickly treat deadly allergies.

What's more, the team found the device worked
fine as an implant for four weeks, even after
scar tissue formed around it. Siddharth
Krishnan, the lead author of the study, which
appeared in Nature Biomedical Engineering this
week, noted it might last a whole lot longer
than that. "The idea is you would have enough
doses that can provide this therapeutic rescue
event over a significant period of time," he
explained. "We don’t know exactly what that is
– maybe a year, maybe a few years, and we’re
currently working on establishing what the
optimal lifetime is. But then after that, it
would need to be replaced."

This device could be a boon for hypoglycemic
people who can't administer glucagon
injections on their own, as well as those who
suddenly encounter extreme cases of the
condition, which makes it hard to swallow any
edibles that could help raise blood sugar
quickly.

It can also make life easier for those who
live with diabetes and use continuous glucose
monitors, as it could negate the need to
inject glucagon or even manually trigger it –
the device can be designed to receive signals
from those wearables and deliver a dose
without the patient ever having to intervene.

The researchers' next steps involve further
testing of the implant in animals, and
clinical trials with humans within the next
three years.

This device joins a bunch of recent compelling
approaches to tackling hypoglycemia, including
a nanomedicine that can release glucagon in
hypoglycemic conditions in the bloodstream,
and an on/off switch that can be added to
insulin so it manages itself to prevent
hypoglycemia. Treating this condition
effectively could also help people avoid
blindness that can be brought on by low blood
sugar levels, as researchers noted earlier
this year.

WHERE CLINICAL EXCELLENCE MEETS HUMAN COMPASSION: THE WORK OF NOA PAKTER AT SHEBA MEDICAL CENTERAt Sheba Medical Center,...
19/06/2025

WHERE CLINICAL EXCELLENCE MEETS HUMAN
COMPASSION: THE WORK OF NOA PAKTER AT SHEBA
MEDICAL CENTER

At Sheba Medical Center, patient care extends
beyond clinical excellence. It is shaped by an
effort to understand and respond to the human
experience behind every medical case. Leading
this effort is Noa Pakter, Project Manager in
Sheba’s Patient Experience Division, whose
work embodies the center’s holistic approach
to compassionate care, especially during times
of crisis.
Since the start of the war, Noa Pakter has
assumed a central role in managing the arrival
and recovery experience of wounded soldiers,
many of whom are transferred directly from
combat zones.

“From the moment they arrive, we’re there to
surround them with care and wrap them with
love,” she shares. “Whatever they need, we’re
here to help. They protected us—and now it’s
our turn to protect them.”

Her team’s mission is not only to meet
physical needs but to offer a stabilizing and
empathetic environment, recognizing that
trauma care begins with safety and trust.

Preparing for the Return of Hostages: Every
Detail Matters
In parallel, Noa has been instrumental in
preparing Sheba for the return of hostages, a
process that demands discretion, sensitivity,
and thoughtful planning. Her team remains on
standby around the clock, working behind the
scenes to create an environment tailored to
each individual’s needs and preferences, even
before they arrive.

“We learn about who they are, what makes them
happy, what they like to eat, even their
clothing size,” she explains. “From the
lighting in the room to the scent in the air
and the softness of the bedding,” every detail
is considered. “We care for them and for their
families, too. We want them to feel supported
and loved, so they have a positive experience
during their time here at Sheba.”

A Human-Centered Team Culture
Noa emphasizes the vital role of her team, a
group of professionals she describes as
“extraordinary” in their empathy,
attentiveness, and quiet strength. “They lead
with humility, strength, and this incredible
ability to really see people,” she says. The
work of the Patient Experience Division is not
guided by checklists but by intention,
purpose, and emotional intelligence.

In her words, being part of Sheba means
working in a place that understands healing is
multidimensional. It involves restoring
dignity, fostering connection, and creating
space for joy, especially in the most
difficult moments.

In an era where medical institutions are
redefining care delivery, the work led by Noa
Pakter at Sheba Medical Center serves as a
model for patient-centered hospitality and
psychosocial support. Her team’s efforts
reinforce a core value at Sheba: that healing
is as much about how we care as what we treat.

AI transforms healthcare while human touch emerges as market differentiatorHealthcare leaders who blend tech innovation ...
12/06/2025

AI transforms healthcare while human touch
emerges as market differentiator

Healthcare leaders who blend tech innovation
with empathy are now capturing market share,
as automation handles routine tasks and
providers focus on patient relationships.

As healthcare continues its rapid evolution
post-pandemic, the intersection of
technological innovation and human-centered
care presents both unprecedented challenges
and opportunities. After several years on the
frontlines of medical innovation, I've
observed key shifts in how healthcare
organizations approach technology adoption and
implementation, particularly today as AI
transforms the industry.

Technology Adoption: Breaking Down Barriers
Perhaps the most significant shift in recent
years has been healthcare organizations'
increasing willingness to embrace risk and
explore the use of new technologies.
Artificial intelligence (AI) has finally
reached a critical mass of accessibility,
affordability, and user-friendliness that was
previously unattainable.

I recall my experience with a startup in 2018
where we used a voice assistant to develop a
program that automatically collected clinical
histories using Natural Language Processing, a
precursor to the technology behind today's
large language models. Back then, the concept
was promising but cumbersome, with significant
friction points hindering implementation.
Fast-forward to 2025, and we see these
technologies seamlessly integrated into our
daily workflows, following the adoption curve
of other transformative technologies like
social media platforms: easy to use, widely
adopted, continuously improving.

Where AI Delivers Immediate Value
The areas currently seeing the most
significant benefit from AI implementation are
those with lower regulatory barriers, what I
call "efficiency tasks", such as clinical
documentation through ambient technology and
automating back-office functions such as
claims processing and calendar management.
These "efficiency tasks" applications do not
face the same regulatory hurdles as AI-powered
medical devices or clinical decision support
systems because they do not trigger extensive
regulatory review, allowing for faster
implementation and value generation. As a
result, "efficiency tasks" represent the low-
hanging fruit where AI is already making
substantial impacts, in contrast to more
complex clinical applications like AI-assisted
diagnosis and treatment planning.

Overcoming Implementation Challenges
The primary barrier to innovation
implementation isn't technological, it's
behavioral. Healthcare professionals naturally
resist disrupting established workflows,
especially when current processes seem "good
enough." The common refrain of "if it's not
broken, don't fix it" poses a significant
challenge to innovation adoption.

Address

UK Address: PLUM TREE HOUSE - OLD VICARAGE LANE SWINDON - UNITED KINGDOM - SN3 4SH : Dubai Address:Office No. 2108, Jumeirah Bay Tower - Dubai - United Arab Emirates.
Dubai

Opening Hours

Monday 08:00 - 18:00
Tuesday 08:00 - 18:00
Wednesday 08:00 - 18:00
Thursday 08:00 - 18:00
Sunday 08:00 - 18:00

Alerts

Be the first to know and let us send you an email when Evorin pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Evorin pharma:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category